$5m Placement for Drug Registration and Treatment Pipeline
Filed with ASX · · 3 pages · English
● Funds expected to: ○ advance pivotal clinical trials for EMD-003 and EMD-004 important first steps towards registration with the TGA ○ define US FDA regulatory pathwaysfor Emyria’s growing drug development programs ○ initiate scoping of a psychedelic-assisted therapy clinical trialin partnership with Mind Medicine Australia ○ support further data analysis and IP filing based on Emyria Data ahead of
Earlier from Emyria
- Emyria and Cann Partner to Register CBD Product
- Emyria Adds Second Clinical Site in Perth
- Emyria adds second Emerald Clinic in Melbourne
- Emyria wins digital health monitoring grant with UWA
- FDA Position on RWE to Guide Registration
Later from Emyria
- Emyria and MMA launch MDMA-assisted therapy program for PTSD
- Emyria Obtains TGA Approval for Medical Grade Monitoring App
- Emyria Data Validated, Care Model Reduces Opioids
- Emyria Advances EMD-004 Program Towards Registration
- Emyria to Develop Novel Psychedelics Pipeline with UWA
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria